“NEOADJUVANT FOR PATIENTS WITH HIGH AND VERY HIGH RISK PROSTATE CANCER” (2019) Voprosy onkologii, 65(5), pp. 726–735. doi:10.37469/0507-3758-2019-65-5-726-735.